Amryt Pharma has announced that all resolutions presented to shareholders at the shareholder meetings held to consider and vote on the proposed acquisition of Amryt by Chiesi Farmaceutici have been duly passed. The waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the Transaction has expired. However, the closing of the Transaction is still subject to certain other regulatory approvals and the satisfaction or waiver of certain other customary closing conditions, including obtaining the sanction of the High Court of Justice of England and Wales. Amryt expects the Transaction to close in the second quarter of 2023.
Amryt Pharma Plc (“Amryt”) (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that all resolutions presented to shareholders at today’s shareholder meetings held to consider and vote on the proposed acquisition of Amryt by Chiesi Farmaceutici S.p.A., (the “Transaction”) were duly passed. The full text of each resolution was included in the notice of the shareholder meetings posted to shareholders on February 16, 2023, and is available on the Company’s website www.amrytpharma.com/investors.
The waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the Transaction has expired. The closing of the Transaction remains subject to certain other regulatory approvals and the satisfaction or waiver of certain other customary closing conditions, including obtaining the sanction of the High Court of Justice of England and Wales. Amryt expects the Transaction will close in the second quarter of 2023.
Source: BioSpace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
